RT @PeterNeumann11: ICER has gained stature by doing numerous things right but can improve further https://t.co/oiiAiJTpdD @icer_review @Ap…
RT @CADTH_ACMTS: ICYMI: "ICER’s Revised Value Assessment Framework for 2017–2019: A Critique" #HTA #healtheconomics https://t.co/affEkRVnMd
RT @PeterNeumann11: ICER has gained stature by doing numerous things right but can improve further https://t.co/oiiAiJTpdD @icer_review @Ap…
RT @CADTH_ACMTS: ICYMI: "ICER’s Revised Value Assessment Framework for 2017–2019: A Critique" #HTA #healtheconomics https://t.co/affEkRVnMd
ICYMI: "ICER’s Revised Value Assessment Framework for 2017–2019: A Critique" #HTA #healtheconomics https://t.co/affEkRVnMd
RT @CADTH_ACMTS: .@icer_review..."has surfaced as a credible response to demand among US private payers for #HTA to counter high drug (and…
RT @CADTH_ACMTS: .@icer_review..."has surfaced as a credible response to demand among US private payers for #HTA to counter high drug (and…
.@icer_review..."has surfaced as a credible response to demand among US private payers for #HTA to counter high drug (and device) prices." https://t.co/Yf2QOmHQix
RT @ApplHealthEcon: Blogs from @icer_review and @PeterNeumann11 about his commentary https://t.co/QqmKPrRifM https://t.co/CtjFWJpQRV https:…
RT @ApplHealthEcon: Blogs from @icer_review and @PeterNeumann11 about his commentary https://t.co/QqmKPrRifM https://t.co/CtjFWJpQRV https:…
Blogs from @icer_review and @PeterNeumann11 about his commentary https://t.co/QqmKPrRifM https://t.co/CtjFWJpQRV https://t.co/vaXd1J8zg1
ICER's Revised Value Assessment Framework for 2017–2019: A Critique /via @ApplHealthEcon https://t.co/3a27KyrvH6 #healtheconomics
RT @PeterNeumann11: Despite drawbacks, ICER has advanced U.S. debates about value and affordability. Our new commentary: https://t.co/oii…
RT @PeterNeumann11: ICER has gained stature by doing numerous things right but can improve further https://t.co/oiiAiJTpdD @icer_review @Ap…
RT @kchalkidou: An American NICE? https://t.co/k3wNU5DsOL How much US insurers afford to pay for new drugs? ICER's value framework https://…
RT @kchalkidou: An American NICE? https://t.co/k3wNU5DsOL How much US insurers afford to pay for new drugs? ICER's value framework https://…
RT @PeterNeumann11: ICER has gained stature by doing numerous things right but can improve further https://t.co/oiiAiJTpdD @icer_review @Ap…
RT @PeterNeumann11: ICER has gained stature by doing numerous things right but can improve further https://t.co/oiiAiJTpdD @icer_review @Ap…
RT @PeterNeumann11: ICER has gained stature by doing numerous things right but can improve further https://t.co/oiiAiJTpdD @icer_review @Ap…
RT @PeterNeumann11: ICER has gained stature by doing numerous things right but can improve further https://t.co/oiiAiJTpdD @icer_review @Ap…
ICER's Revised Value Assessment Framework for 2017–2019: A Critique /via @ApplHealthEcon https://t.co/3a27KyrvH6 #healtheconomics
ICER has gained stature by doing numerous things right but can improve further https://t.co/oiiAiJTpdD @icer_review @ApplHealthEcon
RT @HansSeverens: Finally... the US starts to understand that health care money better be spend wisely! https://t.co/n7jIsfR98p
RT @PeterNeumann11: Despite drawbacks, ICER has advanced U.S. debates about value and affordability. Our new commentary: https://t.co/oii…
RT @PeterNeumann11: My commentary with Josh Cohen on ICER's revised value framework is out in Pharmacoeconomics. https://t.co/oiiAiKb0Cd.
RT @PeterNeumann11: My commentary with Josh Cohen on ICER's revised value framework is out in Pharmacoeconomics. https://t.co/oiiAiKb0Cd.
RT @PeterNeumann11: Despite drawbacks, ICER has advanced U.S. debates about value and affordability. Our new commentary: https://t.co/oii…
RT @PeterNeumann11: My commentary with Josh Cohen on ICER's revised value framework is out in Pharmacoeconomics. https://t.co/oiiAiKb0Cd.
RT @PeterNeumann11: Despite drawbacks, ICER has advanced U.S. debates about value and affordability. Our new commentary: https://t.co/oii…
RT @PeterNeumann11: Despite drawbacks, ICER has advanced U.S. debates about value and affordability. Our new commentary: https://t.co/oii…
RT @PeterNeumann11: Despite drawbacks, ICER has advanced U.S. debates about value and affordability. Our new commentary: https://t.co/oii…
Despite drawbacks, ICER has advanced U.S. debates about value and affordability. Our new commentary: https://t.co/oiiAiKb0Cd @icer_review
RT @PeterNeumann11: My commentary with Josh Cohen on ICER's revised value framework is out in Pharmacoeconomics. https://t.co/oiiAiKb0Cd.
An American NICE? https://t.co/k3wNU5DsOL How much US insurers afford to pay for new drugs? ICER's value framework https://t.co/g8j0MBQSWv
RT @ApplHealthEcon: Comment on @icer_review framework by @PeterNeumann11 &Cohen https://t.co/5fwFXI6O8J - Lingering problems: budget cap, p…
CEVR's @PeterNeumann11 & Josh Cohen provide commentary on @icer_review's revised value framework in #PharmaEconomics https://t.co/HdYt8orSHT
My commentary with Josh Cohen on ICER's revised value framework is out in Pharmacoeconomics. https://t.co/oiiAiKb0Cd.
RT @ApplHealthEcon: Comment on @icer_review framework by @PeterNeumann11 &Cohen https://t.co/5fwFXI6O8J - Lingering problems: budget cap, p…
RT @ApplHealthEcon: Comment on @icer_review framework by @PeterNeumann11 &Cohen https://t.co/5fwFXI6O8J - Lingering problems: budget cap, p…
RT @ApplHealthEcon: Comment on @icer_review framework by @PeterNeumann11 &Cohen https://t.co/5fwFXI6O8J - Lingering problems: budget cap, p…
Comment on @icer_review framework by @PeterNeumann11 &Cohen https://t.co/5fwFXI6O8J - Lingering problems: budget cap, perspective, threshold
@icer_review should provide both healthcare and societal perspectives according to @PeterNeumann11 and Cohen https://t.co/X5rxEyqNp9
#HealthEconJA ICER’s Revised Value Assessment Framework for 2017–2019: A Critique https://t.co/zi8CIvtQmM